Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics has announced promising translational data from its Phase 1/2 trial of CHM CDH17 CAR-T cells, which target cadherin 17, a protein overexpressed in gastrointestinal tumors. The trial showed that the CAR-T cells persisted in patients for up to six months after a single infusion, indicating potential efficacy in treating advanced gastrointestinal cancers. This development enhances Chimeric’s confidence in advancing the clinical dose finding process and could significantly impact its positioning in the oncology cell therapy market.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is a clinical stage cell therapy company focused on developing innovative cell therapies for cancer treatment. The company has a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies, with assets being developed across multiple oncology areas. Chimeric’s team is dedicated to the discovery, development, and commercialization of promising cell therapies, with four clinical stage programs currently underway.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.06M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.